Inflammatory bowel disease (IBD)
Conditions
Interventions
Hemienteral nutrition group:adalimumab biological analogues combined with partial enteral nutrition therapy
Internal nutrition group:adalimumab combined with total enteral nutrition
The adamumab group:adalimumab
Sponsors
The First Affiliated Hospital of Shantou University Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years; 2. The patient was diagnosed with Crohn's disease according to the 2018 Chinese IBD Diagnosis and Treatment Guidelines; 3. Adamumab bioanalogues were prescribed for the first time; 4. Sign the informed consent of the experiment and be willing to participate; 5. No symptoms of gastrointestinal obstruction; 6. Nutritional risk was assessed by management risk screening (NRS2002I>3 points).
Exclusion criteria
Exclusion criteria: 1. Currently enrolled in or planning to participate in any other clinical studies; 2. The patient had contraindications to adalimumab therapy or enteral nutrition; 3. Pregnant patients; 4. Patients with other serious underlying diseases; 5. Poor compliance or drug intolerance; 6. Worsening of the disease; 7. Patients using other immunological agents or hormones.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ratio of clinical response (CDAI decline >=100) to clinical remission (CDAI<150) was achieved; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of endoscopic remission;Changes in body mass index (BMI); | — |
Countries
China
Contacts
Public ContactYu Jing
The First Affiliated Hospital of Shantou University Medical College
Outcome results
None listed